Research and Development, Abbott Japan Co. Ltd, 278 Matsuhidai, Matsudo, Chiba, 270-2214, Japan.
School of Computing, Tokyo Institute of Technology, J2-51, 4259, Nagatsuta-cho, Midori-ku, Yokohama, Kanagawa, 226-8503, Japan.
Anal Bioanal Chem. 2019 Jul;411(17):3789-3800. doi: 10.1007/s00216-019-01878-z. Epub 2019 Jun 3.
MicroRNAs (miRNAs) in a blood sample are usually measured by quantitative reverse transcription PCR (qRT-PCR), microarray, and next-generation sequencing (NGS) which requires time-consuming pre-treatment, manual operation, and a stand-alone instrument. To overcome these disadvantages, miRNA testing has been developed using the automated analyzers routinely used in clinical laboratories. An isothermal DNA amplification reaction was adapted to a fully automated immunoassay analyzer that conducts extraction, amplification, and detection processes at 37 °C in 44 min. In a reaction vessel, a pre-designed single-stranded signal DNA was amplified in the presence of miRNA, using DNA templates, DNA polymerase, and nicking endonuclease. Then, the amplified signal DNA was hybridized by one DNA probe attached to a magnetic particle and another DNA probe labeled with acridinium ester. After the chemiluminescence reaction, luminescence intensity was automatically measured. The automated assays of cancer-related miRNAs were implemented on the analyzer with throughput of 66 tests per hour. In the assays with one-step amplification, three miRNAs (miR-21-5p, miR-18a-5p, and miR-500a-3p) at concentrations lower than 100 fM were automatically detected and the cross reactivity for miR-21-5p with fifteen similar miRNAs was not higher than 0.02%. In the assay with two-step amplification, detection sensitivity and amplification rate for miR-21-5p were 3 fM and 103-fold, respectively. The coefficient of variations (CVs) in the measurement at the target concentrations from 5 fM to 1000 pM were less than 8%. Furthermore, we also achieved automated nucleic acid detection in human serum. The proposed fully automated miRNA assays showed high sensitivity, low cross reactivity, and reproducibility suitable for clinical use. Graphical abstract.
在血液样本中,微 RNA(miRNA)通常通过定量逆转录 PCR(qRT-PCR)、微阵列和下一代测序(NGS)进行测量,这些方法需要耗时的预处理、手动操作和独立的仪器。为了克服这些缺点,已经开发了使用临床实验室中常规使用的自动化分析仪进行 miRNA 测试。等温 DNA 扩增反应被适应于全自动免疫分析仪,该分析仪在 37°C 下在 44 分钟内进行提取、扩增和检测过程。在反应容器中,在存在 miRNA 的情况下,使用 DNA 模板、DNA 聚合酶和缺口内切酶扩增预设计的单链信号 DNA。然后,扩增的信号 DNA 通过与磁珠连接的一个 DNA 探针和另一个标记有吖啶酯的 DNA 探针杂交。化学发光反应后,自动测量发光强度。在每小时 66 个测试的分析仪上实现了癌症相关 miRNA 的自动化测定。在一步扩增的测定中,在低于 100fM 的浓度下自动检测到三种 miRNA(miR-21-5p、miR-18a-5p 和 miR-500a-3p),并且 miR-21-5p 与十五种类似 miRNA 的交叉反应性不高于 0.02%。在两步扩增的测定中,miR-21-5p 的检测灵敏度和扩增率分别为 3fM 和 103 倍。在靶浓度为 5fM 至 1000pM 的测量中,变异系数(CV)小于 8%。此外,我们还实现了人血清中的自动核酸检测。所提出的全自动 miRNA 测定法具有高灵敏度、低交叉反应性和可重复性,适用于临床应用。